| アブストラクト | OBJECTIVE: We compared the incidence rates of hospitalized infections (HIs) between tocilizumab (TCZ) and other biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in adults aged >/=75 years with rheumatoid arthritis (RA). METHODS: We used a Japanese claims database from Medical Data Vision Co., Ltd (Tokyo, Japan) to perform a retrospective longitudinal population-based study in patients with RA who were prescribed b/tsDMARDs between 2014 and 2019. We calculated adjusted risk ratios (aRRs) for HIs in three age groups (<65, >/=65 and <75, and >/=75 years). RESULTS: Of 5506 patients, 2265 (41.1%) were <65 years, 1709 (31.0%) were 65-74 years, and 1532 (27.8%) were >/=75 years. Crude incidence rates (/100 person-years) of HIs were 3.99, 7.27, and 10.77, respectively. In the oldest group, aRRs (95% confidence interval) for HIs (b/tsDMARDs versus TCZ) were as follows: etanercept, 2.40 (1.24-4.61); adalimumab, 1.90 (0.75-4.83); golimumab, 1.21 (0.66-2.23); and abatacept, 0.89 (0.49-1.62). In the other age groups, the noticeable difference was a lower aRR of etanercept versus TCZ in the youngest group (0.30, 0.11-0.85). CONCLUSION: In patients with RA aged >/=75 years, b/tsDMARDs have a similar risk of HIs to tocilizumab except for etanercept. |
|---|
| ジャーナル名 | Modern rheumatology |
|---|
| Pubmed追加日 | 2023/4/12 |
|---|
| 投稿者 | Harigai, Masayoshi; Fujii, Takao; Sakai, Ryoko; Igarashi, Ataru; Shoji, Ayako; Yamaguchi, Hiroko; Iwasaki, Katsuhiko; Makishima, Misako; Yoshida, Amika; Okada, Norihiro; Yamashita, Katsuhisa; Kawahito, Yutaka |
|---|
| 組織名 | Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical;University School of Medicine, Tokyo, Japan.;Department of Rheumatology and Clinical Immunology, Wakayama Medical University,;Wakayama, Japan.;Department of Public Health and Epidemiology, Meiji Pharmaceutical University,;Tokyo, Japan.;Department of Health Economics & Outcomes Research, Graduate School of;Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.;Unit of Public Health and Preventive Medicine, Yokohama City University of;Medicine, Yokohama, Japan.;Medilead Inc., Tokyo Opera City Tower, Tokyo, Japan.;Chugai Pharmaceutical Co., Ltd, Tokyo, Japan.;Inflammation and Immunology, Graduate School of Medical Science, Kyoto;Prefectural University of Medicine, Kyoto, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37039670/ |
|---|
